Market Cap 3.80B
Revenue (ttm) 0.00
Net Income (ttm) -141.20M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 592,500
Avg Vol 845,698
Day's Range N/A - N/A
Shares Out 71.08M
Stochastic %K 86%
Beta -1.50
Analysts Strong Sell
Price Target $106.44

Company Profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. The company also develops ACCG-2671 and ACCG-3535, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 1978
Address:
601 Gateway Boulevard, Suite 900, South San Francisco, United States
Doozio
Doozio Jul. 3 at 4:36 PM
$GPCR ENTA 🐒🍌🧠⏰♾️
0 · Reply
Kylenorth
Kylenorth Jul. 2 at 2:19 PM
$GPCR BO coming this year!! 120 +
0 · Reply
IM11
IM11 Jul. 1 at 5:29 PM
$SNY I am hoping they announce a buyout of $GPCR between now and that July 30 Q2 report. But just a hunch, no strong evidence other than GPCR running up steadily the past month (potential leak?)
0 · Reply
BioRich
BioRich Jul. 1 at 4:42 PM
$GPCR Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) $VNDA 22) $SHAZ 23) $NRXP 24) GPCR 25) $EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
Quantumup
Quantumup Jul. 1 at 11:11 AM
Cantor reiterated $VKTX Overweight-$100 $NVO $GPCR LLY ZLDPY - RHHBY ABBV AZN Cantor said, In 3Q26, we expect Viking to report data from its ongoing Phase 1 subcutaneous "Maintenance Study" testing injectable GLP-1/GIP dual agonist VK2735 in various new dosing regimens including 1) different titration schema than prior studies or ongoing Phase 3 studies, 2) higher induction doses than previously studied, 3) weekly maintenance dosing after achieving significant weight loss, and 4) monthly maintenance dosing. The setup into the data is sneaky and likely very good so long as the Street is aware that maintenance dosing is a means of retaining as much weight loss as possible, not driving further weight loss or even "flat lining" weight.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 1 at 3:15 AM
$GPCR if we take out 58 tmrw, 70 is next. Mark it
1 · Reply
Chickenisinthepot
Chickenisinthepot Jul. 1 at 12:57 AM
$GPCR 7.5 billion and VKTX whisper is around $12 billion. Seems logical and fair. I heard VKTX turned down $9 already from people in the know.
1 · Reply
GreenHawkz
GreenHawkz Jun. 30 at 7:45 PM
$VKTX even XBI is up more !!! $GPCR UP 4% 😂😂😂😂 news is out on whos being acquired. Not BL’s personal ATM!!!!
0 · Reply
nlrmandate
nlrmandate Jun. 30 at 7:15 PM
$VKTX @saifnila2 💯agree! I'm actually surprised that $GPCR SP is doing as well as it is given that it only has an oral GLP and oral Amylin in late stage testing. They have an Amylin/calcitonin analog and a GIP (and also plan to trial combinations of GLP, GIP, Amylin/cacitonin), but all are at the IND or P1 stage; their website doesn't say whether any of those will be SQ or if they're solely an oral company. VKTX, by contrast has a GLP1/GIP in both oral and SQ late stage p3 testing and Amylin/calcitonin in p1 testing. Clearly Viking's pipeline if much further along. @IM11 needs to do some pipeline research before claiming GSPC has a better chance of a BO at a higher price than Viking. I absolutely DO believe GSPC will be BO, but it's a 10B company in a BO TOPS. JMHO; INSANELY
1 · Reply
Chi_Booth
Chi_Booth Jun. 30 at 5:39 PM
$VKTX $GPCR Here is the xbi vs vktx for the last 15 days. Seems like they are moving in locksteps with xbi outperforming viking in certain days.
1 · Reply
Latest News on GPCR
Structure Therapeutics Transcript: AGM 2026

Jun 17, 2026, 12:00 PM EDT - 17 days ago

Structure Therapeutics Transcript: AGM 2026


The Next Phase Of The Obesity Drug Race

Jun 13, 2026, 2:00 PM EDT - 21 days ago

The Next Phase Of The Obesity Drug Race

LLY NVO


Structure Therapeutics Slides: Corporate presentation

Jun 5, 2026, 7:00 AM EDT - 4 weeks ago

Structure Therapeutics Slides: Corporate presentation


Structure Therapeutics Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Structure Therapeutics Earnings release: Q1 2026


Structure Therapeutics Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 2 months ago

Structure Therapeutics Quarterly report: Q1 2026


Structure Therapeutics initiated with a Buy at Canaccord

2026-04-27T10:00:27.000Z - 2 months ago

Structure Therapeutics initiated with a Buy at Canaccord


Structure Therapeutics Proxy statement: Proxy filing

Apr 23, 2026, 8:00 AM EDT - 2 months ago

Structure Therapeutics Proxy statement: Proxy filing


Structure Therapeutics appoints Matthew Lang as COO

2026-04-14T20:17:51.000Z - 2 months ago

Structure Therapeutics appoints Matthew Lang as COO


Structure Therapeutics Transcript: Study result

Mar 16, 2026, 8:30 AM EDT - 3 months ago

Structure Therapeutics Transcript: Study result


Structure Therapeutics Press release: Study result

Mar 16, 2026, 8:30 AM EDT - 3 months ago

Structure Therapeutics Press release: Study result


Structure Therapeutics Slides: Study result

Mar 16, 2026, 8:30 AM EDT - 3 months ago

Structure Therapeutics Slides: Study result


Structure Therapeutics Annual report: Q4 2025

Feb 26, 2026, 4:00 PM EST - 4 months ago

Structure Therapeutics Annual report: Q4 2025


Structure Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 4:00 PM EST - 4 months ago

Structure Therapeutics Earnings release: Q4 2025


Structure Therapeutics moved to Buy rating at Goldman Sachs

2026-01-19T22:30:27.000Z - 5 months ago

Structure Therapeutics moved to Buy rating at Goldman Sachs

LLY


Structure CEO Ray Stevens talks its obesity drug portfolio

Jan 15, 2026, 6:21 PM EST - 6 months ago

Structure CEO Ray Stevens talks its obesity drug portfolio


Structure Therapeutics rises 14.1%

2026-01-13T17:05:46.000Z - 6 months ago

Structure Therapeutics rises 14.1%


Structure Therapeutics Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 6 months ago

Structure Therapeutics Slides: Corporate presentation


Structure Therapeutics Transcript: Study Update

Dec 8, 2025, 8:30 AM EST - 7 months ago

Structure Therapeutics Transcript: Study Update


Structure Therapeutics Press release: Study Update

Dec 8, 2025, 8:30 AM EST - 7 months ago

Structure Therapeutics Press release: Study Update


Structure Therapeutics Slides: Study Update

Dec 8, 2025, 8:30 AM EST - 7 months ago

Structure Therapeutics Slides: Study Update


Final Trade: UBER, CRWV, GPCR, DIS

Nov 10, 2025, 6:21 PM EST - 8 months ago

Final Trade: UBER, CRWV, GPCR, DIS

CRWV UBER DIS


Structure Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 8 months ago

Structure Therapeutics Quarterly report: Q3 2025


Structure Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 8 months ago

Structure Therapeutics Earnings release: Q3 2025


Fast Money: DAL, ROKU, AAPL, GPCR

Nov 5, 2025, 6:21 PM EST - 8 months ago

Fast Money: DAL, ROKU, AAPL, GPCR

AAPL ROKU DAL


Structure Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Structure Therapeutics Quarterly report: Q2 2025


Structure Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:00 PM EDT - 11 months ago

Structure Therapeutics Earnings release: Q2 2025


Structure Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Earnings release: Q1 2025


Structure Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Structure Therapeutics Quarterly report: Q1 2025


Structure Therapeutics Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Structure Therapeutics Proxy statement: Proxy Filing


Structure Therapeutics CEO on latest GLP-1 developments

Mar 24, 2025, 6:26 PM EDT - 1 year ago

Structure Therapeutics CEO on latest GLP-1 developments


Final Trade: PYPL, UBER, NKE, GPCR

Mar 24, 2025, 6:23 PM EDT - 1 year ago

Final Trade: PYPL, UBER, NKE, GPCR

NKE PYPL UBER


Structure Therapeutics Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Annual report: Q4 2024


Structure Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q4 2024


Structure Therapeutics Transcript: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update


Structure Therapeutics Press release: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update


Structure Therapeutics Slides: Study Update

Dec 17, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update


Structure Therapeutics Transcript: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Transcript: Study Update


Structure Therapeutics Press release: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Press release: Study Update


Structure Therapeutics Slides: Study Update

Nov 13, 2024, 4:30 PM EST - 1 year ago

Structure Therapeutics Slides: Study Update


Structure Therapeutics Quarterly report: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Quarterly report: Q3 2024


Structure Therapeutics Earnings release: Q3 2024

Nov 13, 2024, 4:00 PM EST - 1 year ago

Structure Therapeutics Earnings release: Q3 2024


Structure Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Quarterly report: Q2 2024


Structure Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Earnings release: Q2 2024


Structure Therapeutics CEO on GLP drugs

Jun 11, 2024, 6:37 PM EDT - 2 years ago

Structure Therapeutics CEO on GLP drugs


Structure Therapeutics Transcript: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Transcript: Study Update


Structure Therapeutics Press release: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Press release: Study Update


Structure Therapeutics Slides: Study Update

Jun 3, 2024, 8:30 AM EDT - 2 years ago

Structure Therapeutics Slides: Study Update


Structure Therapeutics Quarterly report: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Quarterly report: Q1 2024


Structure Therapeutics Earnings release: Q1 2024

May 9, 2024, 4:00 PM EDT - 2 years ago

Structure Therapeutics Earnings release: Q1 2024


Structure Therapeutics Proxy statement: Proxy Filing

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Structure Therapeutics Proxy statement: Proxy Filing


Doozio
Doozio Jul. 3 at 4:36 PM
$GPCR ENTA 🐒🍌🧠⏰♾️
0 · Reply
Kylenorth
Kylenorth Jul. 2 at 2:19 PM
$GPCR BO coming this year!! 120 +
0 · Reply
IM11
IM11 Jul. 1 at 5:29 PM
$SNY I am hoping they announce a buyout of $GPCR between now and that July 30 Q2 report. But just a hunch, no strong evidence other than GPCR running up steadily the past month (potential leak?)
0 · Reply
BioRich
BioRich Jul. 1 at 4:42 PM
$GPCR Stocktwits Q2 Quarterly Filing: @BioRich Top 50 portfolio positions: 1) GUTS 2) ABVX 3) IBRX 4) ALT 5) KYTX 6) DAVE 7) CADL 8) MIST 9) UEC 10) OTLK 11) CAPR 12) TGTX 13) SABS 14) NVAX 15) LEGN 16) VKTX 17) OCUL 18) SOFI 19) BBIO 20) SGP 21) $VNDA 22) $SHAZ 23) $NRXP 24) GPCR 25) $EWTX 26) TLSA 27) SKM 28) MLTX 29) SNDX 30) JMIA 31) NKTR 32) VVOS 33) RGNX 35) ARRNF 36) CRMD 37) WVE 38) NUVB 39) SMMT 40) ANNX 41) CGON 42) TEM 43) IVA 44) PSN 45) LGND 46) IMVT 47) MPLT 48)NNE 49) ARDX 50) COGT If I own it, I believe in it. What am I missing? Hold too much? Not enough? Look forward to your feedback! Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
Quantumup
Quantumup Jul. 1 at 11:11 AM
Cantor reiterated $VKTX Overweight-$100 $NVO $GPCR LLY ZLDPY - RHHBY ABBV AZN Cantor said, In 3Q26, we expect Viking to report data from its ongoing Phase 1 subcutaneous "Maintenance Study" testing injectable GLP-1/GIP dual agonist VK2735 in various new dosing regimens including 1) different titration schema than prior studies or ongoing Phase 3 studies, 2) higher induction doses than previously studied, 3) weekly maintenance dosing after achieving significant weight loss, and 4) monthly maintenance dosing. The setup into the data is sneaky and likely very good so long as the Street is aware that maintenance dosing is a means of retaining as much weight loss as possible, not driving further weight loss or even "flat lining" weight.
0 · Reply
BIOTECH_GURU
BIOTECH_GURU Jul. 1 at 3:15 AM
$GPCR if we take out 58 tmrw, 70 is next. Mark it
1 · Reply
Chickenisinthepot
Chickenisinthepot Jul. 1 at 12:57 AM
$GPCR 7.5 billion and VKTX whisper is around $12 billion. Seems logical and fair. I heard VKTX turned down $9 already from people in the know.
1 · Reply
GreenHawkz
GreenHawkz Jun. 30 at 7:45 PM
$VKTX even XBI is up more !!! $GPCR UP 4% 😂😂😂😂 news is out on whos being acquired. Not BL’s personal ATM!!!!
0 · Reply
nlrmandate
nlrmandate Jun. 30 at 7:15 PM
$VKTX @saifnila2 💯agree! I'm actually surprised that $GPCR SP is doing as well as it is given that it only has an oral GLP and oral Amylin in late stage testing. They have an Amylin/calcitonin analog and a GIP (and also plan to trial combinations of GLP, GIP, Amylin/cacitonin), but all are at the IND or P1 stage; their website doesn't say whether any of those will be SQ or if they're solely an oral company. VKTX, by contrast has a GLP1/GIP in both oral and SQ late stage p3 testing and Amylin/calcitonin in p1 testing. Clearly Viking's pipeline if much further along. @IM11 needs to do some pipeline research before claiming GSPC has a better chance of a BO at a higher price than Viking. I absolutely DO believe GSPC will be BO, but it's a 10B company in a BO TOPS. JMHO; INSANELY
1 · Reply
Chi_Booth
Chi_Booth Jun. 30 at 5:39 PM
$VKTX $GPCR Here is the xbi vs vktx for the last 15 days. Seems like they are moving in locksteps with xbi outperforming viking in certain days.
1 · Reply
Stockman824
Stockman824 Jun. 30 at 5:38 PM
$GPCR $VKTX we haven’t gone up like this since the big run. I think XBI is helping but it’s not the reason for this run. Someone(s) out there know more then we do and is slowly, systematically buying a F load of shares!!!!!
1 · Reply
biolover
biolover Jun. 30 at 5:01 PM
$GPCR has other assets beyond GLP1 R. Several patents and an oral amylin in phase 1 ( modified from a scaffold that was published by others years ago ). Overall MC still humble compared to what is there in immunology , neuroscience and oncology. Only issue short term risk from any setback to $LLY orforglipron .. it could harm it big. but long term not a bad play. And for bio hedge funds fans .. they like it. But for certain analyst to call it better than orfor is not accurate. Wt loss will be less prominent with 2.5 mg start Obviously GPCR drug is much weaker than what $VKTX has
0 · Reply
biolover
biolover Jun. 30 at 5:00 PM
$VKTX that is not a sector rotation. There is a leak about BO in obesity and thus Vk and $GPCR up … Vk never outperformed other biotechs in generic rallies since 2024. Thanks for BL leadership.
1 · Reply
IM11
IM11 Jun. 30 at 4:14 PM
$GPCR sure is making a big run for no news since the ADA data. Feels like somebody knows something and before phase 3 start is a prime buyout window. 3 day weekend makes Monday July 6th seem like an announcement possibility?
0 · Reply
Kylenorth
Kylenorth Jun. 30 at 4:06 PM
$GPCR BO coming!!! 130 bucks
0 · Reply
chartistmind
chartistmind Jun. 30 at 3:10 PM
$GPCR 🤦🏻‍♂️ 🤦‍♀️ 🤦
0 · Reply
StocketShip
StocketShip Jun. 30 at 3:05 PM
$GPCR Buyout???
0 · Reply
Theflash88
Theflash88 Jun. 29 at 8:09 PM
$GPCR Where is everyone?? GPCR is on the move!
1 · Reply
IM11
IM11 Jun. 29 at 6:33 PM
$GPCR we are ROLLING! Up around 2% every day for the past month! I know the sector is up but seems like GPCR is up the most (compared to VKTX & KLRA). Anyone else think a buyout announcement may be coming on Monday July 6th?
1 · Reply
Theflash88
Theflash88 Jun. 27 at 12:04 AM
$GPCR $LLY $VKTX Own both.
1 · Reply
wwmeinc
wwmeinc Jun. 26 at 9:58 PM
$VKTX ..Curious as to what Gemini has in its database when prompted to compare $GPCR and $VKTX from a WS angle...What is the data showing in financial terms...so its 'readings' are strictly in the eye of the "cloud"...maybe a CHATGPT has its readings..so here goes..glta! "The Final Consensus...Wall Street does not view this as a situation where one stock must go to zero for the other to win. The market opportunity for anti-obesity drugs is projected to cross > $100 billion, leaving plenty of room for both configurations. Today’s capital flow....proves that the street is funding both angles: Hedge funds are actively cornering the VKTX float to capture explosive, high-efficacy clinical data moves and acquisition spikes, while conservative asset managers are banking a multi-billion dollar floor in GPCR to own the cheapest mass-market manufacturing infrastructure of tomorrow. Holding VKTX exposes you directly to the highest-octane alpha generator on the biotech tape." ***risk/rewards
0 · Reply
biolover
biolover Jun. 26 at 8:20 PM
$GPCR $VKTX GPCR could be BO by idiots at MRK or FDA could report first case of Dili from $LLY Orfo and GPCR go down 80% .. wait and see which happens first.
1 · Reply